Premium
Secreted APP and amyloid beta quantification in SH‐SY5Y cell media using high sensitivity AlphaLISA kits
Author(s) -
Hohenauer Krystyna,
Anani Shihadeh,
Marcil Alexandre,
Roby Philippe,
Parent Stephane,
Dahan Sophie
Publication year - 2010
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.24.1_supplement.lb462
Subject(s) - amyloid precursor protein , alpha secretase , chemistry , amyloid precursor protein secretase , endogeny , cell culture , amyloid beta , cell , cleavage (geology) , amyloid (mycology) , peptide , biochemistry , microbiology and biotechnology , alzheimer's disease , biology , disease , medicine , inorganic chemistry , genetics , paleontology , fracture (geology)
The aggregation and accumulation of amyloid beta peptides is one of the pathological hallmarks of Alzheimer's disease (AD). Amyloid beta is produced by sequential proteolytic cleavage of Amyloid Precursor Protein (APP) by beta‐ and gamma‐secretase, which are plausible molecular targets for AD treatment. Thus, identification of modulators of these secretases could lead to new therapeutics for this prevalent and debilitating disease. SH‐SY5Y are human neuroblastoma cells that express APP and the various secretases that cleave this membrane‐bound protein into sAPPβ, sAPPα and amyloid beta peptides. We have developed new highly sensitive and specific AlphaLISA kits that allow the detection of endogenous amounts of these various APP metabolites. Specific inhibitors of alpha‐, beta‐ and gamma‐secretase were used to modulate the relative activities of these enzymes. Application of these inhibitors resulted in characteristic signature levels of product sAPPα, sAPPβ, Aβ 1–40 and Aβ x‐40 (defined as the combined amount of both Aβ 1–40 and Aβ 17–40) from SH‐SY5Y cell culture supernatants. These results show that the new AlphaLISA kits have sufficient sensitivity and specificity to study this pathway, even in wild‐type cells that do not overexpress APP or BACE. The Z′‐factor obtained for these cell‐based secretase assays was greater than 0.6, indicating reproducible and robust assays for HTS. In summary, these new AlphaLISA detection kits can accurately quantitate endogenous APP cleavage products. This will in turn result in a better understanding of the APP degradation pathway and facilitate the identification of novel therapeutic drugs for the treatment of Alzheimer's disease.